Aché launched 35 products in 2021 following its strong ability to meet physician expectations and consumer needs. Hormonal and vitamin solutions are among the new products, in addition to treatments for the central nervous system, inflammatory, cardiac and dermatological pathologies.

Our current pipeline includes 193 projects under development. Eight projects from Brazilian biodiversity, with first launch scheduled for 2026 and 13 radical innovation projects. Aché’s investment in innovation was BRL 153 million in 2021 and is expected to invest more than BRL 200 million in 2022.

Since 2012 we have a stake in Bionovis, a biotechnology company formed by Aché and three other national laboratories. Through CPV (Care for Life, in portuguese), we offer consumers and health professionals service provision and access to products.

The constant investment in manufacturing and logistics technologies, and the conscious use of non-renewable natural resources, involving the value chain, enable Aché to provide products safely and effectively, reinforcing their excellence.